Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-29

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rectal cancer is one of the common malignant tumors of the digestive tract. Some patients with rectal cancer are already advanced tumors when they are first diagnosed. At this time, the tumor has local infiltration, the probability of recurrence and metastasis after surgical resection is high, and even radical tumor resection cannot be performed. Neoadjuvant chemotherapy and radiotherapy have become one of the important treatment methods for these patients to increase the rate of radical tumor resection. However, a series of side effects of neoadjuvant radiotherapy can even continue after the end of radiotherapy, and even increase the incidence of postoperative complications. Superselective arterial interventional chemotherapy has been widely used in preoperative neoadjuvant chemotherapy for various tumors, and its efficacy in rectal cancer has also been confirmed. In addition, as a hot spot in tumor treatment, tumor immunotherapy has shown exciting effects in the NICHE study of neoadjuvant immunotherapy before colon cancer surgery. Moreover, Oxaliplatin is a classic chemotherapeutic drug that induces Immunogenic cell death effects, which induce antitumor immunity.

Therefore, in order to optimize the preoperative neoadjuvant therapy plan, the investigators propose a treatment method of superselective arterial chemoembolization combined with immunotherapy and systemic chemotherapy, in order to obtain better preoperative conversion therapy effect and reduce the adverse reactions of neoadjuvant therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

NCT07161115

Rectal Adenocarcinoma

NOT_YET_RECRUITING PHASE2

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

NCT04543695

Rectal Cancer

ACTIVE_NOT_RECRUITING PHASE2

Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial

NCT03038256

Rectal Cancer Pathological Complete Response Disease Free Survival

UNKNOWN PHASE2

Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC

NCT05307198

Rectal Neoplasms

UNKNOWN PHASE2

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

NCT05845268

Locally Advanced Rectal Cancer

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental arm

Group Type EXPERIMENTAL

Arterial chemoembolization

Intervention Type PROCEDURE

The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.

Tislelizumab Injection

Intervention Type DRUG

Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.

XELOX

Intervention Type DRUG

Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.

Pelvic MRI

Intervention Type DIAGNOSTIC_TEST

Pelvic MRI to evaluate efficacy

Laparoscopic radical resection of rectal cancer

Intervention Type PROCEDURE

Surgical treatment for patients who meet the surgical conditions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arterial chemoembolization

The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.

Intervention Type PROCEDURE

Tislelizumab Injection

Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.

Intervention Type DRUG

XELOX

Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.

Intervention Type DRUG

Pelvic MRI

Pelvic MRI to evaluate efficacy

Intervention Type DIAGNOSTIC_TEST

Laparoscopic radical resection of rectal cancer

Surgical treatment for patients who meet the surgical conditions

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Pathologically confirmed rectal adenocarcinoma (immunohistochemistry, polymerase chain reaction(PCR) or next-generation sequencing(NGS) sequencing methods are acceptable).
2. Magnetic resonance imaging (MRI) measurement of tumor inferior margin ≤12cm from the anus.
3. MRI staging is cT3-4 N0 or cT1-4 N+, no multiple primary cancers or distant metastasis.
4. Life expectancy ≥ 1 year.
5. No anti-tumor therapy, no contraindications to interventional embolization, immunotherapy and chemotherapy.
6. Patients who understand the study protocol and are willing to participate in this study provide written informed consent.

Exclusion Criteria

1. Refuse to participate in this study.
2. Multifocal colorectal cancer.
3. Past history of malignancy, excluding basal cell carcinoma/papillary thyroid carcinoma/various types of carcinoma in situ.
4. Inability to receive chemotherapy, such as but not limited to bone marrow suppression, etc.
5. Major organ diseases (such as but not limited to chronic obstructive pulmonary disease, coronary heart disease and renal insufficiency, etc.) during acute exacerbation and or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia and myocarditis, etc.), American Society of Anesthesiologists(ASA) score \> 3.
6. Mental disability or illiteracy or language and communication barriers cannot understand the research protocol.
7. There are contraindications to arterial puncture, such as but not limited to severe arteriosclerosis or even atresia, coagulation dysfunction, long-term use of anticoagulants and cannot be stopped, etc.
8. Obstruction or high risk of obstruction by rectal tumor and/or bleeding and/or perforation.
9. Peripheral sensory nerve disorder, unable to receive oxaliplatin-based chemotherapy.
10. Lateral pelvic lymph node metastasis (mainly supplied by the internal iliac artery).
11. Pregnancy or breastfeeding.
12. Contraindications for MRI。
13. Consecutive use of corticosteroids for more than 3 days within 1 month before signing the consent form。
14. MRI assessment was T4b or MRF positive。
15. Other scenarios deemed inappropriate by the investigators for this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No